J Korean Med Assoc Search

CLOSE


J Korean Med Assoc > Volume 46(3); 2003 > Article
Kang: Pharmacologic Therapy in Patients with Chronic Renal Failure

Abstract

Chronic renal failure (CRF) is a functional diagnosis characterized by a progressive and generally irreversible decline in glomerular filtration rate (GFR). It is caused by a number of diseases, most commonly diabetes, glomerulonephritis, hypertension and the genetic diseases. The renal function of CRF patients declines by unrelenting progressive loss of nephron that persists long after the inciting event. CRF is not a curable disease. The aim of the treatment of CRF is to halt or delay the progression of renal failure and amelioration of symptoms, not to cure of the disease. Systemic hypertension, glomerular hypertension, proteinuria and protein - rich diet contribute to the progression of renal failure. Restriction of dietary protein intake help to preserve residual renal function. Among the antihypertensives, angiotensin converting enzyme inhibitor (ACEI) is the drug of choice for blood pressure control in CRF patients, because this class of drug reduces intraglomerular pressure. There is a growing awareness of a need not only to identify CRF patients at an earlier stage in the disease process, but also to initiate treatment strategies earlier to delay progression of CRF and to define the optimal time required to prepare CRF patients for renal replacement therapy. Early referral to the nephrologist is important for timely intervention. The consequences of late referral include increased morbidity and mortality. There is also an impact on patient's quality of life and missed opportunities for pre- emptive transplantation. Late referral also limits therapeutic options, and these limitations exert adverse effects on long-term outcomes once patients are on dialysis.

References

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413.

2. Mendelssohn DC, Barrett BJ, Brownscombe LM, Ethier J, Greenberg DE, Toffelmire EB, et al. Elevated level of serum creatinine: recommendations for management and referral. CMAJ 1999;161:413-417.

3. Levin A. Consequences of late referral on patient outcomes. Nephrol Dial Transplant 2000;15:Suppl 3. 8-13.

4. Fogo AB. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int Suppl 2000;57:75. S15-S21.

5. Klahr S, Morrissey J. Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage. Kidney Int Suppl 2002;62(82):S23-S26.

Table 1
jkma-46-246-i001-l.jpg


ABOUT
ARTICLE CATEGORY

Browse all articles >

ARCHIVES
FOR CONTRIBUTORS
Editorial Office
37 Ichon-ro 46-gil, Yongsan-gu, Seoul
Tel: +82-2-6350-6562    Fax: +82-2-792-5208    E-mail: jkmamaster@gmail.com                

Copyright © 2024 by Korean Medical Association.

Developed in M2PI

Close layer
prev next